Command Palette

Search for a command to run...

MARKSANS

178.89-1.48%
Market Cap
₹8,227.19 Cr
Stock P/E
23.50
ROCE
22.50%
ROE
16.89%
Book Value
₹55.72

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

POSITIVES
  • Q1 FY26 revenue rose 5% YoY to INR620 crores, with US revenue up 30.6% YoY to INR327.6 crores.
  • Gross margin expanded to 57.8% in Q1 FY26 (up 209 bps), with gross profit up 8.9% YoY.
NEGATIVES
  • EBITDA margin declined 560 bps YoY to 16.1% due to higher employee costs and one-time provisions.
  • UK market faced seasonality and price erosion, contributing to weaker performance.

Peers Summary

Sector Leader

Marksans Pharma Ltd. presents a balanced financial profile with solid growth metrics and healthy profitability ratios, positioning it as a strong contender in the Pharmaceuticals & Drugs sector. It outperforms several peers in key financial metrics while maintaining a lower debt level, making it an attractive option for investors looking for stability and growth.

Key Points
  • Marksans Pharma shows strong revenue growth and reasonable EPS growth compared to peers.
  • It maintains a low debt equity ratio, indicating low financial risk.
  • The company has competitive profitability margins, particularly in the pharmaceutical sector.
Top Performers
Dr. Reddy's Laboratories Ltd.

Highest ROE, ROA, and ROCE, alongside solid profitability metrics.

Cipla Ltd.

Strong profitability with the lowest PE ratio, indicating potential undervaluation.

Mankind Pharma Ltd.

High revenue growth and EPS growth rates, indicating rapid expansion.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.